EUVIMEDEUVIMED entdecken
Crossref

Preclinical evaluation and first-in-human study of 68Ga- and Al18F-Labeled PSMA/FAP bispecific tracers for prostate cancer imaging

Xinlin Wang, Ming Wang, Yimin Chen, Ruotong Jian, Haonan Yu, Xiaojun Zhang, Jinming Zhang, Shaobo Yao, Jin Du, Mengchao Cui iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07591-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Xinlin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Glutamate Carboxypeptidase II, Positron Emission Tomography Computed Tomography, Antigens, Surface. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Joint Funds for the Innovation of Science and Technology, Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyAntigens, SurfaceFluorine RadioisotopesMembrane ProteinsSerine EndopeptidasesMaleHumansAnimalsGallium RadioisotopesMiceCell Line, TumorRadioactive TracersTissue DistributionEndopeptidases

Stichwörter der Autor:innen

Bispecific tracerFibroblast activation proteinFirst-in-humanPETProstate-specific membrane antigen

Substanzen

Gallium RadioisotopesGlutamate Carboxypeptidase IIAntigens, SurfaceFluorine RadioisotopesFOLH1 protein, humanMembrane ProteinsSerine EndopeptidasesRadioactive TracersEndopeptidasesFluorine-18

Autor:innen und Institutionen

  • Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
  • Department of Nuclear Technology and Application, China Institute of Atomic Energy, Beijing, 102413, China.
  • Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China.
  • Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
  • Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China. yaoshaobo008@163.com.
  • Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China. cmc@bnu.edu.cn.

ORCID-Profile: Mengchao Cui

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Joint Funds for the Innovation of Science and Technology, Fujian Province

Zitieren

APA

Wang, X., Wang, M., Chen, Y., Jian, R., Yu, H., Zhang, X., Zhang, J., Yao, S., Du, J., & Cui, M. (2026). Preclinical evaluation and first-in-human study of 68Ga- and Al18F-Labeled PSMA/FAP bispecific tracers for prostate cancer imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07591-7

Vancouver

Wang X, Wang M, Chen Y, Jian R, Yu H, Zhang X, et al. Preclinical evaluation and first-in-human study of 68Ga- and Al18F-Labeled PSMA/FAP bispecific tracers for prostate cancer imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07591-7

BibTeX
@article{Wang2026,
  author = {Wang, Xinlin and Wang, Ming and Chen, Yimin and Jian, Ruotong and Yu, Haonan and Zhang, Xiaojun and Zhang, Jinming and Yao, Shaobo and Du, Jin and Cui, Mengchao},
  title = {Preclinical evaluation and first-in-human study of 68Ga- and Al18F-Labeled PSMA/FAP bispecific tracers for prostate cancer imaging},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07591-7}
}
Kostenlos starten →